** Shares of drug developer Apogee Therapeutics APGE.O rise 1.66% to $78.35 premarket

** Co says its experimental drug zumilokibart showed strong results in an early-stage trial for adults with mild-to-moderate asthma

** Zumilokibart cut airway inflammation in the adults - AGPE

** Effect lasted up to 32 weeks after a single dose; no serious side effects reported, says co

** Co's zumilokibart also being tested for atopic dermatitis, a chronic skin condition - APGE

** Apogee expects more trial data this year and aims to start late-stage studies next year

** As of last close, stock up ~3% over the past year

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))